HPC2/ELAC2 polymorphisms and prostate cancer risk: analysis by age of onset of disease

por Meitz, J C, Edwards, S M, Easton, D F, Murkin, A, Ardern-Jones, A, Jackson, R A, Williams, S, Dearnaley, D P, Stratton, M R, Houlston, R S, Eeles, R A
Publicado 2002

ATM polymorphisms as risk factors for prostate cancer development

por Angèle, S, Falconer, A, Edwards, S M, Dörk, T, Bremer, M, Moullan, N, Chapot, B, Muir, K, Houlston, R, Norman, A R, Bullock, S, Hope, Q, Meitz, J, Dearnaley, D, Dowe, A, Southgate, C, Ardern-Jones, A, Easton, D F, Eeles, R A, Hall, J
Publicado 2004

Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis

por Edwards, S M, Evans, D G R, Hope, Q, Norman, A R, Barbachano, Y, Bullock, S, Kote-Jarai, Z, Meitz, J, Falconer, A, Osin, P, Fisher, C, Guy, M, Jhavar, S G, Hall, A L, O'Brien, L T, Gehr-Swain, B N, Wilkinson, R A, Forrest, M S, Dearnaley, D P, Ardern-Jones, A T, Page, E C, Easton, D F, Eeles, R A
Publicado 2010